Last reviewed · How we verify
cyclophosphamide/azathioprine
Cyclophosphamide is an alkylating agent that interferes with DNA replication, while azathioprine is a purine synthesis inhibitor that suppresses the immune system.
Cyclophosphamide is an alkylating agent that interferes with DNA replication, while azathioprine is a purine synthesis inhibitor that suppresses the immune system. Used for Treatment of certain types of cancer, such as lymphomas and leukemias, and autoimmune diseases, such as rheumatoid arthritis and lupus, Prevention of organ rejection in transplant patients.
At a glance
| Generic name | cyclophosphamide/azathioprine |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Alkylating agent/Purine synthesis inhibitor |
| Modality | Small molecule |
| Therapeutic area | Oncology/Immunology |
| Phase | Phase 3 |
Mechanism of action
Cyclophosphamide works by adding an alkyl group to the DNA of cancer cells, causing cross-linking and interfering with DNA replication. Azathioprine, on the other hand, is converted into 6-mercaptopurine, which inhibits the synthesis of purines, thereby suppressing the immune system. This dual mechanism of action makes cyclophosphamide/azathioprine effective in treating various types of cancer and autoimmune diseases.
Approved indications
- Treatment of certain types of cancer, such as lymphomas and leukemias, and autoimmune diseases, such as rheumatoid arthritis and lupus
- Prevention of organ rejection in transplant patients
Common side effects
- Myelosuppression
- Nausea and vomiting
- Diarrhea
- Infections
- Hair loss
Key clinical trials
- Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease (PHASE4)
- Rituximab in Eosinophilic Granulomatosis With Polyangiitis (PHASE3)
- Different Immunosuppressive Treatment in iMN (PHASE3)
- BDB-001 Phase III Trial in ANCA-Associated Vasculitis (PHASE3)
- Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) (PHASE3)
- Reduced Intensity Transplantation for Severe Sickle Cell Disease (PHASE2)
- Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease (PHASE2)
- Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cyclophosphamide/azathioprine CI brief — competitive landscape report
- cyclophosphamide/azathioprine updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI